68.57

2.22% 1.49

Mbx Biosciences Inc (MBX)

Overview News Price History Discussions Forecast

Mbx Biosciences Inc stock is traded at $68.57, with a volume of 503.13K. It is up +2.22% in the last 24 hours and up +21.17% over the past month. MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

Previous Close:

$67.08

Open:

$67

24h Volume:

503.13K

Relative Volume:

0.65

Market Cap:

$3.30B

Revenue:

Net Income/Loss:

$-86.97M

P/E Ratio:

-28.35

EPS:

-2.4189

Net Cash Flow:

$-81.88M

1W Performance:

+1.11%

1M Performance:

+21.17%

6M Performance:

+80.02%

1Y Performance:

+419.08%

1-Day Range:

$65.01

$68.84

1-Week Range:

$65.01

$68.84

52-Week Range:

$9.63

$72.64

Mbx Biosciences Inc Stock (MBX) Company Profile

Name

Mbx Biosciences Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(317) 989-3100

Address

11711 N. MERIDIAN STREET, CARMEL

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

MBX's Discussions on Twitter

Compare MBX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBX Mbx Biosciences Inc	68.57	3.23B	0	-86.97M	-81.88M	-2.4189
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Overweight
Dec-04-25	Initiated	Goldman	Sell
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy
Aug-15-25	Resumed	Jefferies	Buy
Aug-05-25	Initiated	Mizuho	Outperform
Jul-16-25	Initiated	Oppenheimer	Outperform
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	JP Morgan	Overweight
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Stifel	Buy

View All

Mbx Biosciences Inc Stock (MBX) Latest News

Aug 14, 2026

Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - Stock Titan

Aug 14, 2026

Aug 10, 2026

Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan

Aug 10, 2026

OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan

Aug 10, 2026

Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo

Aug 10, 2026

Aug 09, 2026